Lv3
244 积分 2021-04-09 加入
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
9天前
已完结
LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC
9天前
已关闭
2O Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)
9天前
已关闭
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
9天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
9天前
已完结
Second primary malignancies associated with renal cell carcinoma: influence of histologic type
24天前
已完结
Second primary malignancies associated with renal cell carcinoma: influence of histologic type
24天前
已完结
Genomic profiling of primary and metastatic thyroid cancers
25天前
已完结
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib
28天前
已完结
HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology
29天前
已完结
皖公网安备34019202002308
